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Abstract 
 
Myelomeningocele and Hydrocephalus in Uganda: The Intersection of Culture, 
Supportive Care, and Long-Term Survival. Ernest J Wright III (Sponsored by Dr. 
Dennis Spencer). Department of Neurosurgery, Yale School of Medicine, New Haven, 
CT.  
 
The treatment of neurosurgical disease in the developing world presents 
challenges on numerous levels, not the least of which are the litany of logistical and 
infrastructural barriers which stand in the way of delivering care. The scarcity of 
neurosurgeons combined with limited mobility in developing countries requires a 
reconsideration of approaches to treatment; this is particularly true of 
ventriculoperitoneal (VP) shunt insertion for the treatment of hydrocephalus. While VP 
shunt implantation is the mainstay of treatment in the United States, it is prone to failure 
requiring rapid access to neurosurgical care making shunt dependency a dangerous 
proposition in this setting. Endoscopic third ventriculostomy (ETV) offers an alternative 
to VP shunt dependency and has been shown to be effective in treating hydrocephalus at 
intervals of up to 14 months.  
The purpose of this study is to compare the five-year survival for children treated 
with endoscopic third ventriculostomy (ETV) to those treated with ventriculoperitoneal 
(VP) shunt implantation for myelomeningocele-associated hydrocephalus. Because of the 
well known dangers of shunt dependency, it is hypothesized that patients treated with 
ETV will have a survival advantage when compared with patients treated with VPS at a 
follow-up interval of five years.  
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In order to address this hypothesis, a retrospective observational study of children 
treated with ETV or VP shunt implantation for myelomeningocele-related hydrocephalus 
at the CURE Children’s Hospital of Uganda was carried out, including a control group 
consisting of myelomeningocele patients who had not developed hydrocephalus.  
Survival status was determined for 128 of 131 study participants (98%). 47/128 (37%) 
of patients had expired at five years post-treatment, and 55/128 (42%) patients had expired 
at a mean follow-up interval of 84.4 months. Only two cases of death were attributable to 
the development of hydrocephalus, none as a result of treatment failure. Kaplan-Meier 
survival analysis found no statistically significant relationship between survival and 
method of treatment for hydrocephalus (p=0.45), sex of patient (p=0.53), HIV status 
(p=0.69), age at repair ( p=0.34), or myelomeningocele level (p=0.12).  Survival analysis 
performed for districts with community based rehabilitation (CBR) programs and 
districts without CBR programs revealed a significant interaction (p=0.001).  
The uniformly high mortality across all groups suggests that the chief causes of 
long-term mortality are both powerful and independent of hydrocephalus. The only 
correlation with survival identified in this study, the presence of a CBR program 
providing in-home rehabilitation, fulfills both of these criteria: myelomeningocele patients 
require long-term rehabilitation regardless of the development of hydrocephalus and 
these programs exert a powerful influence on survival. This substantial difference in long-
term survival highlights the fact that children in communities without CBR programs are 
not receiving life-saving supportive care, in part due to a lack of parental understanding of 
the need for longitudinal care. Established cultural beliefs about myelomeningocele, 
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hydrocephalus, and disability in general also hampered efforts to improve survival. 
Understanding the practical barriers to the delivery of care in a developing country as well 
as the cultural mores through which diseases are understood are critical to effectively 
treating disease across cultures and continents.  
 
 
 
 
 
 
 
 
 
Acknowledgements 
 
I would like to thank Drs. Benjamin Warf and Dennis Spencer for their kindness and 
mentorship over the past years which have culminated in this thesis project. I would also 
like to thank all of the residents and faculty members in the Department of Neurosurgery 
at the Yale School of Medicine who have supported and nurtured my interest in 
neurosurgery, Dr. Abhaya Kulkarni for offering his statistical knowledge and guidance in 
data analysis, and the Yale Office of Student Research for funding this project. 
 
I would especially like to thank my parents, Ernest and Alica Wright, as well as my sister 
Nicole Wright for their unconditional love and belief in me. And finally, I owe a great 
debt to my dear friends: Whitney Tolpinrud, whose love and support buoyed me during 
my time in Uganda, and Bryan Hong, a true friend and gifted illustrator who gave so 
generously of his time provide the images for our children’s book Everyone is Different. 
 
This thesis is not the product of any one person, but rather is a product of the 
contributions of the people mentioned above. For them and all the ways that they have 
touched my life, I will always be grateful.  
	  	  
4	  
Table of  Contents 
 
Introduction……………………………………………………………………………………………………..…5  
 Neurosurgery in the Developing World……………………………………………………….6 
 Hydorecphalus in Uganda………………………………………………………………………….7  
 Alternative Approaches to the Treatment of Hydrocephalus…………………………..9 
Statement of Purpose……………………………………………………………………………………………13 
Methods …………………………………………………………………………………………………………….14 
Study Site………………………………………………………………………………………………..14 
 Patient Selection……………………………………………………………………………………….15 
 Experimental Design…………………………………………………………………………………15 
 Outcome Measures and Patient Tracking…………………………………………………….15 
 Determination of Hydrocephalus………………………………………………………………..17  
 Analysis/Statistical Methods………………………………………………………………………17 
Results……………………………………………………………………………………………………………….17  
Study Population and Follow-Up Status……………………………………………………..17 
 Survival Analyses………………………………………………………………………………………18 
 Development of Hydrocephalus…………………………………………………………………24 
Discussion………………………………………………………………………………………………………….25  
Determinants of Long-Term Survival………………………………………………………….25 
 Importance of Accessible Long-Term Care………………………………………………….27 
 The Importance of Culture and Communcation in Good Outcomes………………28 
 A Shift in Focus and New Initiatives at CCHU…………………………………………..30 
Conclusion…………………………………………………………………………………………………………33 
Appendix A: Everyone is Different..………………………………………………………………………34 
Appendix B: Portraits from Mbale…………………..……………………………………………………41 
 
 
 
 
 
 
	  	  
5	  
Introduction 
 
Mbale, Uganda is a frontier town of sorts: situated five hours from the capital 
Kampala, it is the last major stop on the road to the Northwestern border with Sudan 
and Kenya. It is an unlikely place to receive neurosurgical care, yet since the year 2000 it 
has been home to the CURE Children’s Hospital of Uganda, the sole treatment center 
dedicated to pediatric neurosurgery in sub-Saharan Africa. When the Hospital opened, it 
brought to the region for the first time the possibility of survival for children born with 
hydrocephalus and myelomeningocele, diseases that are most often fatal when untreated. 
In two modern neurosurgical operating suites treatment for these diseases is dispensed in 
the model of the developed world where children receive an initial surgical procedure at 
the hospital and are discharged home with instructions to return to the Hospital for 
follow-up care. With such a neurosurgical outpost utilizing proven treatment paradigms, 
it is expected that the results should be dramatic: where few children had survived these 
diseases in the past, few should be dying of these ailments in the present. The efficacy of 
these treatments at intervals beyond 14 months is unknown however, as greater than 70% 
of these patients have been lost to follow-up five years after their initial treatment. The 
fate of these patients, whether they are surviving or expired, and ultimately whether 
treatment has been effective in intervening in the natural course of disease is unknown. 
What follows is an attempt to answer this question, but also to better understand how to 
adapt a technically complex and technology-dependent field such as neurosurgery to the 
setting of a developing country where even the electricity to power the many devices that 
modern neurosurgeons depend on cannot be taken for granted.  
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Neurosurgery in the Developing World 
There are few areas within medicine that have changed as much in the span of a 
half-century as neurosurgery. Advancements beginning with the implementation of the 
operating microscope in 1957 heralded the age of modern neurosurgery, in which 
dauntingly complex pathology is now treated routinely with greater precision, less 
morbidity, and lower mortality(1, 2). While the field has made a practice of conscripting 
cutting-edge technology to advance the frontiers of neurosurgery, the fact remains that 
the overwhelming majority of the six billion citizens of the world have languished with no 
neurosurgical care at all. A full 60% of the world’s neurosurgeons administer care to just 
14% of the global population; the remaining 40%, 9,686 neurosurgeons, are responsible 
for 4.66 billion individuals(3). In addition to inequities in the distribution of neurosurgical 
talent, neurosurgically treated illness exerts a disproportionate toll on the citizens of the 
developing world. Hydrocephalus, a disease of excess cerebrospinal fluid in the 
ventricular system of the brain, has been shown to have a higher prevalence and affect a 
larger number of children in East Africa (4). Neural tube defects, debilitating congenital 
malformations requiring neurosurgical repair of which the most severe variants are 
termed myelomeningocele, are the most frequently encountered congenital malformation 
in sub-Saharan Africa(5). Given this disproportionate disease burden and the scarcity of 
neurosurgical care, attention must be given to the treatment of neurosurgical diseases in 
the third world to ensure that as the frontiers of neurosurgery are advanced in the first 
world the remainder of the world’s population is not left behind.  
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 The necessary solution to this problem lies not in simply exporting first world 
treatment paradigms, but in developing treatments tailored to the developing world. The 
factors which complicate daily life in developing countries- namely shortcomings of 
government, disparities in purchasing power, and a lack of basic infrastructure- also 
present unique challenges to the delivery of neurosurgical care.  Unstable or inefficient 
systems of government prevent the administration of an effective public health apparatus, 
disparities in purchasing power place medical devices and pharmaceuticals beyond reach 
of the majority of the populace, and a lack of investment in infrastructure presents barriers 
to both communication and travel. First world treatment paradigms that take these 
things for granted are doomed to fail in this setting. The challenging realities of life in the 
developing world necessitate a unique approach to treatment which takes into account 
the unique limitations of treating disease in a resource-limited setting.  
 
Hydrocephalus in Uganda 
 
The necessity for a considered approach to neurosurgical disease in the 
developing world is illustrated by examining efforts in Uganda to treat hydrocephalus. 
Uganda is emblematic of many developing countries in its shortage of trained physicians 
rendering specialized care: there are only four neurosurgeons serving its population of 
30,000,000 citizens(4, 6). Further exacerbating this scarcity is the fact that most 
healthcare providers are located in urban settings while the majority of the populace is 
dispersed throughout rural areas: three of the four neurosurgeons are located in the 
capital city Kampala while 87% of the population lives outside of urbanized population 
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centers(6, 7). For the relatively few Ugandans with access to a neurosurgeon, treatment 
remains elusive because of the prohibitive cost of neurosurgical care. The price of the 
implantable hardware which comprises the mainstay of treatment for hydrocephalus in 
the US is $650, more than one and a half times the gross national income per capita of 
$420 and an exorbitant sum for the half of the Ugandan population living on less than a 
dollar a day(7, 8). The dearth of neurosurgeons combined with their geographic 
sequestration and the lack of affordable treatment options places first world neurosurgical 
care outside of the reach of the vast majority of the Ugandan population.  
Beyond these myriad challenges endemic to developing countries that stand in the 
way of the delivery of medical care, the nature of disease itself can differ when presenting 
in the developing world. This point is well illustrated by comparing the causes, 
presentation, and sequelae associated with hydrocephalus as it presents in the United 
States and Uganda. While hydrocephalus in the United States is most often congenital in 
origin(9), hydrocephalus in Uganda is most often secondary to infection(10, 11). In the 
United States and most developing nations, hydrocephalus is often detected when a 
child’s head circumference departs from normal growth curves during routine health 
screening. In Uganda where such screening is rare, hydrocephalus presents at a much 
more advanced stage as gross cranial enlargement with overt signs of increased 
intracranial pressure such as nausea and vomiting or paralysis of upward gaze(10). 
Perhaps most importantly in terms of long-term survival, routine complications that are 
considered benign in developed countries can have far more serious consequences in the 
setting of a developing country. Hydrocephalus is commonly treated with a 
	  	  
9	  
ventriculoperitoneal shunt (VPS) device that connects the ventricular system of the brain 
to the peritoneal cavity, creating a path of egress for excess intraventricular cerebrospinal 
fluid. Shunt infection and malfunction are common, manageable complications given 
rapid access to neurosurgical care; however in a setting where antibiotics are unavailable 
and neurosurgical care a day’s journey or more these complications can be lethal. Given 
these fundamental differences in etiology, stage at presentation, and complications, it can 
be said that hydrocephalus in the United States and Uganda share a common 
pathophysiological basis but little else.  
The challenges and barriers to the delivery of healthcare in the developing world 
are protean. In Uganda, factors both intrinsic and extrinsic to medicine fashion 
hydrocephalus as a distinct pathological entity in a setting of limited resources and 
trained personnel. In this setting where simple tasks are complicated and traditionally 
manageable complications take on lethal consequences, a departure from conventional 
treatment paradigms is required to safely and successfully treat hydrocephalus.  
 
Alternative Approaches to the Treatment of  Hydrocephalus 
 
Ventriculoperitoneal shunt insertion is generally held to be the standard of care for 
the treatment of hydrocephalus(9). There is no published data on the morbidity and 
mortality associated with shunt failure in developing nations. However, the extensive 
body of work enumerating the morbidity and mortality associated with shunt dependency 
in developed countries suggests that shunts fail at high rates and with regularity 
throughout the lifetime of the patient. The most comprehensive trial to date on shunt 
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failure found that over half of ventriculoperitoneal shunts fail within two years of 
implantation, which is in accord with previously reported failure rates in the literature(12-
15). Beyond this high initial failure rate, shunt dependency is an ever-present danger as 
shunts continue to fail throughout the lifetime of the patient at a rate of 5% per annum(16). 
While shunt infection and failure are manageable complications given appropriate 
antibiotics and rapid access to neurosurgical care, in a setting where neurosurgeons and 
antibiotics are scarce shunt dependency is presumably a dangerous proposition.  
Endoscopic third ventriculostomy (ETV) offers an alternative to shunt 
implantation and shunt dependency for the treatment of hydrocephalus by creating an 
alternative communication between the ventricular system and the subarachnoid space 
through fenestration of the floor of the third ventricle. Third ventriculostomy has been 
employed since the dawn of modern neurosurgery for the treatment of hydrocephalus: the 
first third ventriculostomy was performed by Dandy in 1922 with the first endoscopic 
procedure by urologist Walter Mixter in 1923 for which he provided successful treatment 
of non-communicating hydrocephalus in a nine-month old child(17). In the ensuing 
decades, ETV was performed under stereotactic or ultrasound guidance with varying 
degrees of success. The development of silicone and improvements in valve design in the 
latter half of the 1950’s led to ETV being superseded by VP shunt implantation for the 
treatment of hydrocephalus. In recent years however, advances in neuroendoscopy have 
led to a resurgence of interest in ETV.  
ETV represents an attractive alternative to VP shunting for the treatment of 
hydrocephalus in the developing world. Avoiding implantation of shunt hardware has 
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multiple benefits: not only does this obviate the per-procedure cost of a medical implant, 
but the risk of infection is reduced substantially because no foreign bodies are introduced 
into the patient. Most importantly, an alternative to shunt implantation allows one to 
circumvent the dangers of shunt dependency and malfunction that have been well 
documented in the United States and throughout much of the developed world.    
Through a series of studies performed at the CURE Children’s Hospital of 
Uganda (CCHU), Warf et al have sought to define a role for ETV in the treatment of 
hydrocephalus in the developing world(8, 10, 18, 19). In a prospective study involving 229 
patients with hydrocephalus treated by ETV, Warf et al examined the interaction 
between efficacy of ETV and several categorical variables including age at treatment, 
cause of hydrocephalus (infectious vs. non-infectious), and patency of the cerebral 
aqueduct(10).  The overall success rate of 59% obscures the fact that the success of ETV 
varied widely between age groups and hydrocephalus of differing etiology. ETV was 
highly effective in patients greater than one year of age, with success rates of 81% in cases 
of non-postinfectious hydrocephalus (NPIHC) and 90% in postinfectious hydrocephalus 
(PIHC). In patients less than a year of age ETV was markedly less effective: 59% of 
patients with PIHC and just 40% of patients with NPIHC were successfully treated 
with ETV.  However, in patients less than one year of age those with an obstructed 
cerebral aqueduct (as assessed by fourth ventricular size on ultrasound) were well suited 
to treatment by ETV with a success rate of 70%. Based on these findings, Warf contends 
that ETV can be considered for primary treatment of hydrocephalus patients older than 
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one year of age irrespective of etiology and in patients younger than one year of age with 
PIHC and a closed aqueduct.  
In a subsequent prospective study involving 550 patients, Warf sought to 
characterize the potential benefits of combining choroid plexus cauterization (CPC) with 
ETV for the treatment of hydrocephalus(18). While there was no demonstrated benefit in 
patients operated on at one year of age or greater, patients less than one year of age 
received a significant benefit from the addition of CPC with 66% of patients being 
effectively treated in comparison to 47% for ETV alone. Notably, the follow-up intervals 
for the two groups differed significantly with a mean follow-up of 9 months for the 
ETV/CPC group and 19.2 months for the ETV group, leaving open to question the 
possibility that late failure in the ETV/CPC group may have diminished the claimed 
benefit of the combined procedure. The benefits of combining ETV with CPC are even 
more dramatic in several subgroups: the success rate in NPIHC increased from 38% to 
70% with the addition of CPC, and from 35% to 76% in cases of myelomeningocele-
associated hydrocephalus.  
Given the promising results of the combined ETV/CPC procedure in the 
treatment of myelomeningocele-associated hydrocephalus, Warf et al undertook a 
subsequent prospective study involving 115 patients with myelomeningocele-associated 
hydrocephalus treated with ETV/CPC to establish the efficacy of the combined 
procedure at intervals of one year or greater(19). It was found that ETV/CPC was 
effective in 76% of patients at mean follow-up of 19 months. Further, when ETV failure 
occurred the failure presented before 10 months in all patients, and before 6 months 
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almost 90% of patients. These results suggest that ETV/CPC is an effective treatment for 
myelomeningocele-associated hydrocephalus and that treatment failure occurs relatively 
early in the post-operative course, averting the lifelong surveillance required with shunt 
dependency.  
While these studies provide an evidentiary basis for the idea that ETV and 
combined ETV/CPC in particular offer a genuine alternative to shunt implantation for 
the treatment of hydrocephalus, the all-important question remains whether ETV/CPC 
offers an actual survival benefit in comparison to VP shunt implantation for the treatment 
of hydrocephalus. This is the question that this study seeks to address. 
 
Statement of  Purpose: Specific Hypothesis and Aims 
 
The purpose of this study is to determine the five-year survival for children treated with 
ETV or VP shunt implantation for myelomeningocele-associated hydrocephalus between 
2000 and 2005 at the CURE Children’s Hospital of Uganda.  
 
Specifically, I hypothesize that either ETV or the combined ETV/CPC procedure is 
associated with a lower mortality rate than VP shunt implantation for the treatment of 
myelomeningocele-associated hydrocephalus in Southeastern Uganda at a follow-up 
interval of five years.  
 
Additional aims of this study include elucidating the long-term outcome for children with 
myelomeningocele and hydrocephalus in East Africa, which is heretofore unknown.  
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Methods  
 
Study Site 
In order to address this hypothesis, the author undertook a retrospective 
observational study of children treated with ETV, ETV/CPC, or VPS implantation for 
hydrocephalus at the CURE Children’s Hospital of Uganda (CCHU). 
CCHU located in Mbale, Uganda is sub-Saharan Africa’s only dedicated 
pediatric neurosurgical hospital with one attending neurosurgeon performing over 1,000 
procedures per year. CCHU represents an ideal site for this study by virtue of its location 
and existing population of hydrocephalus patients treated with ETV and VPS since the 
year 2000. 
After receiving approval from the institutional review boards of CCHU and 
Children’s Hospital Boston, the author relocated to Mbale for patient selection and data 
collection under the guidance of Dr. Benjamin Warf and Dr. Dennis Spencer.  
Patient Selection 
 
All patients who present to CCHU are entered into a database containing 
identifying information, demographic data, diagnosis, and a record of all surgical 
procedures and follow-up visits. A list of prospective participants in this study was 
generated by searching this database for myelomeningocele patients presenting between 
the year 2000 and the end of 2004, yielding a follow-up interval of five years or greater. 
Because of the difficulty involved in tracking patients living at distances of more than one 
days travel from CCHU, this list was restricted to patients residing in the sixteen 
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districts of southeastern Uganda. This list was further restricted to patients who had 
survived longer than one month after surgery to eliminate early deaths due to surgical 
complications, patients who had a minimum of six months of follow-up to eliminate those 
who failed to return for any follow-up appointments, and patients who presented before 
six months of age to eliminate cases of delayed myelomeningocele closure. 
Experimental  design 
 
From these criteria participants in the study were identified and divided into three 
groups: two treatment groups and one control group. Participants were segregated by 
treatment method into an ETV group including patients who received either an ETV or 
combined ETV/CPC, and a VP shunt group. The control group consisted of 
myelomeningocele patients who had not required any treatment for hydrocephalus.  
The mode of primary treatment was chosen as a function of date at presentation: 
patients presenting for the treatment of hydrocephalus between 2000 and October 2001 
were treated with VPS, between October 2001 and February 2003 ETV, and from 
February 2003 onwards the combined ETV/CPC procedure. Patients who failed 
endoscopic treatment were treated with VP shunt implantation.  
Outcome measures and patient tracking 
 
The outcomes for this study are survival status and the development of 
hydrocephalus. A patient was considered alive if he/she had been seen at the most recent 
annual follow-up visit or at greater than five years of age. The survival status of patients 
who had missed their last follow-up visit was unknown. Efforts were made to locate these 
patients by conducting home visits in the patient’s villages. When families were located, 
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the survival of the patient was ascertained and the family was encouraged to return to the 
hospital for follow-up care if the patient was alive. Patients who could not be found 
despite these exhaustive efforts were considered definitively lost to follow-up and labeled 
as such.  
A patient was deemed expired if expiration was noted in their medical record or if 
the patient’s parents had indicated that the patient had expired at a home visit. In cases 
where patients had expired, efforts were made to determine the date of death and 
circumstances surrounding the death through an extensive questionnaire (Fig 1) with the 
ultimate goal of distinguishing deaths due to hydrocephalus from those of other causes. 
 
Figure 1: Cause of Death Questionnaire featuring open-ended questions and checklist of 
symptoms to elicit circumstances surrounding a patient’s death 
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Determination of hydrocephalus  
 
Those patients noted to have developed hydrocephalus in their hospital charts 
and those who died with a constellation of symptoms indicative of increased intracranial 
pressure (nausea and vomiting, headache, progressive lethargy) were considered to have 
developed hydrocephalus. Patients up to date with follow up appointments but without 
signs or symptoms associated with hydrocephalus were considered not to have developed 
hydrocephalus. Patients who were initially lost to follow-up but found alive without 
receiving any subsequent neurosurgical treatment after myelomeningocele closure were 
considered not treated for hydrocephalus, as were patients who expired without evidence 
of increased intracranial pressure and patients definitively lost to follow-up. 
Analysis/statistical  methods 
 
Kaplan-Meier survival curves were constructed to estimate population survival 
from this sample. The log-rank test was used to assess the interaction between survival 
and categorical variables including method of treatment, myelomeningocele lesion level, 
development of hydrocephalus, gender, and HIV status. The univariate Cox proportional 
hazards model was used to examine the effect of age at closure on survival. These analyses 
were performed by Dr. Abhaya Kulkarni. 
 
 
Results 
 
Study Population and Follow-Up Status 
 
Between the year 2000 and 2005, 224 patients had a myelomeningocele closed at 
CCHU. 140 patients met the inclusion criteria for this study. 41 patients were known to 
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have expired per hospital records; nine because of death attributed to peri-operative 
mortality and resultantly were excluded from this analysis of long-term survival (Table 
1)(19). 23 patients were seen in clinic at a follow-up interval of greater than five years and 
considered surviving for the purposes of this study. Survival status was not known for 76 
patients. 71 patients were visited in their home villages. Survival status was determined via 
telephone for two patients because of relocation to a district outside of the southeastern 
Uganda. Three patients were ultimately lost to follow-up despite all efforts, with survival 
status unknown.  
Cause of Death Number of Patients (n=9) 
Aspiration 2 
Meningitis 2 
Ventriculitis 1 
Cardiac Arrest (unknown etiology) 1 
Anesthesia Complication 1 
Suffocation in Bed 1 
Unidentified Illness 1 
Table 1: Patient mortality during the perioperative period (within one month of surgery). 
There were no known failures of treatment for hydrocephalus leading to death in the 
perioperative period.  
 
Survival  Analyses 
 
F0r the 131 patients included in the analysis, survival status was ascertained for 128 
(98%) patients. At five years post-treatment, 81/128 patients were surviving and 47/128 
expired, yielding five-year survival and mortality rates of 63% and 37% respectively. At the 
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time of data collection, 73/128 (56%) patients were alive at a mean follow-up interval of 
84.4 months and 55/128 (42%) patients were found to have expired (Figure 2). 
Figure 2: Kaplan-Meier survival curve for all study participants. The initial 12-24 months 
following treatment represents the greatest threat to survival, although mortality 
continues steadily throughout the time period measured in this study with 37% of study 
participants expired at five years after treatment. 
 
Of the 55 patients who expired, a cause of death was ascertained through medical 
records or by inference based on the symptoms described in the Cause of Death 
Questionnaire for 35 patients (64% of the instances of death). The causes of death are 
described in Table 2. Notably, only two cases of death occurred with symptoms 
suggestive of increased intracranial pressure consistent with the development of 
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hydrocephalus. These two patients had not been treated for hydrocephalus; as such, 
neither can be considered treatment failures.  
Cause of Death Number of Patients (n=55) 
Unknown 20 
Malaria 11 
Unspecified febrile illness 5 
Anemia, Malnutrition, Dehydration 4 
Gastroenteritis 3 
New onset hydrocephalus 2 
Parental neglect 2 
Pneumonia 2 
Measles 1 
Pyelonephritis 1 
Encephalitis 1 
Ventriculitis (post-ETV) 1 
Severe burns 1 
Chiari 1 
Table 2: Causes of death in expired study participants, with only two cases of death 
attributable to hydrocephalus. Notably, these two patients did not receive treatment for 
hydrocephalus and as such cannot be considered failures of treatment.  
 
Survival analysis found no statistically significant relationship between survival 
and method of treatment for hydrocephalus (p=0.45, Figure 3a), sex of patient (p=0.53), 
HIV status (p=0.69), or age at repair (range 1-126 days of age, mean 20.6 days, median 8 
days, p=0.34). The interaction between anatomical myelomeningocele level and survival 
approached but failed to achieve statistical significance (p=0.12, Figure 3b).  
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Figure 3a: Kaplan-Meier survival curves for treatment groups and the control group 
 
Figure 3b: Kaplan-Meier survival curves for lumbar/sacral and thoracic/thoracolumbar 
myelomeningocele lesions.  
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Survival rates varied widely by district, with no discernable geographic trend to explain 
the variation in mortality (Figure 4). Because a number of districts contributed very few 
patients to this study, with four districts contributing less than five patients (Table 4), 
survival analysis by individual district was not attempted. However, survival analysis was 
performed for districts with community based rehabilitation (CBR) programs (five 
districts, n=48 patients) and districts without CBR programs (11 districts, n=83 
patients). This revealed the only statistically significant interaction in this study, between 
the presence of a CBR program and five year survival, with a p value of 0.001 (Figure 5).  
 
Figure 4: Mortality rates by district. There is no readily discernable geographic trend 
which explains the widely varying mortality rates across districts.  
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District Total  Number of 
Patients 
Number 
Surviving (%) 
Number 
Expired (%) 
Bugiri 3 1 (33%) 2 (66%) 
Busia 5 3 (60%) 2 (40%) 
Iganga 9 5 (56%) 4 (44%) 
Jinja 9 4 (44%) 5 (56%) 
Kampala 6 5 (83%) 1 (17%) 
Kamuli 7 6 (86%) 1 (14%) 
Kapchorwa 4 1 (25%) 3 (75%) 
Katakwi 2 0 (0%) 2 (100%) 
Kumi 14 10 (71%) 4 (29%) 
Mayuge 7 4 (57%) 3 (43%) 
Mbale 23 7 (30%) 16 (70%) 
Mukono 2 0 (0%) 2 (100%) 
Pallisa 8 7 (88%) 1 (12%) 
Sironko 9 4 (44%) 5 (56%) 
Soroti 7 4 (57%) 3 (43%) 
Tororo 16 12 (75%) 4 (25%) 
 
Table 4: Patient number, mortality, and survival by individual district. Mortality (and 
conversely survival) varied widely across districts. However, the variation in the number 
of patients contributed by individual districts prohibited survival analysis by individual 
district.  
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Figure 5: Kaplan-Meier survival curves for districts with and without community based 
rehabilitation (CBR) programs. Note the dramatic divergence between survival curves 
and the substantially lower mortality in districts with CBR programs.  
 
Development of  hydrocephalus 
 
Of the 131 patients in the study, 67 (51%) had received treatment for hydrocephalus 
at the time of data collection. 64 (49%) had not required treatment at the time of data 
collection. Of those requiring treatment for hydrocephalus, 39 patients were primarily 
treated with endoscopy and 28 primarily treated with shunt implantation. ETV was 
successful in 9/17 (53%) patients, and combined ETV/CPC was successful in 17/22 (77%) 
patients. 13 patients failed endoscopic treatment and had ventriculoperitoneal shunts 
implanted. For the 13 patients who failed endoscopic treatment, all failures occurred 
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within nine months and 12/13 (92%) occurred within six months of initial endoscopic 
treatment.  
 
Discussion 
 
Little is known about the fate of patients with myelomeningocele in sub-Saharan 
Africa. Of the handful of studies reported in the literature, most are descriptive 
epidemiological studies(20, 21) and the few studies which attempt to describe the course 
of myelomeningocele suffer from a very small sample size or limited follow-up(22-24). The 
study reported here involving over 100 patients followed for a minimum of five years with 
less than 5% of the study population lost to follow-up is the first to offer insight into the 
challenges and consequences of myelomeningocele in sub-Saharan Africa over the long 
term.  
Determinants of  Long-Term Survival  
 
The primary objective of this study is to investigate whether the theorized benefits 
of ETV and the avoidance of shunt dependency translate into an actual long-term survival 
benefit for patients with myelomeningocele-related hydrocephalus living in a developing 
country. Of the 131 patients who met the inclusion criteria for this study, survival status 
was ascertained and verified for 128 patients (98%) at a mean follow-up interval of 84.4 
months, yielding a robust data set. Based on this data, Kaplan-Meier survival analysis 
revealed no interaction between treatment modality and survival at five years post-
treatment (p=0.45, Fig 3a). Of interest is the finding that there is no difference in survival 
between the treatment groups and the control group, which required no treatment for 
hydrocephalus, suggesting that the factors influencing long-term survival may be 
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altogether independent of the development or treatment of hydrocephalus. This idea is 
supported by the results of attempts to elucidate a cause of death for expired patients: 
hydrocephalus was implicated in only 4/55 (7%) of deaths (Fig 2). The fact that there was 
no correlation identified between survival and a host of categorical variables (sex, HIV 
status, age at repair, anatomical myelomeningocele level) suggests that the chief 
determinants of long-term survival may be powerful enough to obviate the more subtle 
influence of these categorical variables on survival.  
 The idea that there are powerful yet unidentified determinants of long-term 
survival in this population is lent credence by the exceedingly high mortality rate for the 
participants in this study, which stands at 36% at five years of age. This is significantly 
higher than 20-25% mortality reported in earlier studies of myelomeningocele in sub-
Saharan Africa; this difference is likely attributable to the shorter follow-up intervals of 
these earlier studies(23). By comparison, the most recent UNICEF figures available for 
Uganda place the under-5 mortality rate at 18%, making mortality among the participants 
of this study double that of the general population. With these figures in mind, 
elucidating the primary determinants of mortality is of great importance in prolonging 
survival for this population of patients.  
Insight into one of the primary determinants of long-term survival can be found 
through examining an unexpected finding of this study: the large variability in mortality 
across districts. Despite the uniformly high mortality among all study participants, 
mortality rates for individual districts ranged from 12-100%. Although this can in part be 
attributed to the fact that some districts contributed very small numbers of patients and 
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are thus susceptible to errors of random sampling, mortality rates among the three 
districts contributing the most patients varied considerably from 25 to 70% suggesting a 
genuine and substantial variation in mortality rates across districts.  
A closer examination of the three districts contributing the largest number of 
patients to the study (Mbale, Tororo, and Kumi) reveals a potential explanation for this 
disparity (Fig 4). These three contiguous districts are in close geographical proximity and 
as such share many demographic characteristics. Despite this fact, they have dramatically 
different mortality rates: 25% in Tororo, 29% in Kumi, and 70% in Mbale. These results 
are particularly surprising given that Mbale district, where the CURE Children’s 
Hospital of Uganda is located, has one of the highest mortality rates among the districts 
included in the study. An extensive search for potential explanatory factors revealed a key 
dissimilarity between the two districts with dramatically lower mortality rates and Mbale 
district: the existence of a community based rehabilitation (CBR) program that offers in-
home support and training to parents of children with myelomeningocele. Survival 
analysis of the interaction between the presence of a CBR program and five year survival 
revealed a dramatic survival advantage in districts with CBR, as is reflected in the 
Kalpan-Meier survival curve (Fig 5).  
The Importance of Accessible Long-Term Care 
 
The importance of long-term supportive care for myelomeningocele patients is 
well established, with a “life-long commitment by patient, family, and treating medical 
personnel” required for long-term survival(25). This is certainly no less true in Uganda, 
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although the provision of such comprehensive, longitudinal care is far more difficult given 
the lack of a public health infrastructure and the limitations of resources.  
Studies in the United States and Europe have demonstrated that long-term 
mortality in Myelomeningocele is attributable to secondary effects of disease, most 
commonly renal failure as a consequence of urinary incontinence(26, 27). In 
acknowledgement of this fact, CCHU has programs in place to provide the materials and 
instruction to treat urine and bowel incontinence free of charge. However these programs 
are poorly utilized as reflected in the minority of patients returning for follow-up care: of 
the 96 patients still alive at the time of the study, 73 (74%) had not returned for follow-up 
at CCHU. With critical, life-saving follow-up care being offered free of charge, why were 
the majority of patients languishing without such care in their home villages? 
The importance of culture and communication in good outcomes 
 
Understanding the reasons for the poor utilization of follow-up care is crucial to 
prolonging survival in this group of children. Part of the answer to this quandary is 
logistical: travel in Uganda is both difficult and costly, making periodic returns to the 
hospital impractical for many. However, conversations with the caregivers of these 
patients in their home villages proved to be particularly illuminating in providing insight 
into the reasons behind the lack of utilization of follow-up care. This author found that 
most parents simply did not understand the need to return for follow-up care. This in turn 
stemmed from a general lack of understanding of their child’s disease, treatment, or 
prognosis. The majority of parents had no knowledge of the long-term sequelae of 
myelomeningocele or of the perils that ensue when these sequelae are left untreated. 
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Consequently, many caregivers saw no need to invest the time and money to return to the 
hospital. Furthermore, many were misinformed about their child’s prognosis: a number of 
parents expressed anger that their child was unable to walk, not having been told that the 
myelomeningocele would render their child irreversibly paralyzed and instead believing 
that the paralysis was a result of a medical error. This did untold damage to the trust 
between caregivers and doctors. While some parents held the expectation that their child 
would walk, others believed that an early death was an unavoidable consequence of 
disease and consequently abandoned the children with the logic that any resources 
invested in the child would be wasted. In a culture where great meaning is ascribed to 
names, the names chosen for these children reflect the hopelessness of these parents: Atoh 
meaning this child will die, Onono meaning waste of time, or Ajok meaning why has god 
cursed me. Clearly, failures in communication led to a lack of understanding and 
misplaced expectations which hampered efforts to provide essential longitudinal care, 
thereby making a substantial contribution to long-term mortality.  
These findings underscore the fact that the education and participation of 
caregivers in patient care plans are anything but a peripheral concern, particularly in a 
resource-limited setting such as this. While there is a tendency in situations of scarcity to 
streamline care by distilling treatment down to its most essential elements in the name of 
saving more lives, it would be unwise to do so at the expense of long-term survival. 
Ensuring that caregivers have a vested commitment to the treatment plan is an essential 
element of treatment, as essential as the initial surgical procedure or longitudinal follow-
up care, all of which are necessary for long-term survival.  
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With all this in mind, the role and the need for community-based rehabilitation is 
ever more clearly defined. Community-based rehabilitation programs address both of the 
barriers to the utilization of long-term supportive care identified here. First, they are 
based in the patient’s home communities obviating the need for travel. Second, their 
constant presence in the community makes them an ideal vehicle for educating caregivers, 
with the ultimate goal being to make these caregivers vested participants in their child’s 
plan of care. The efficacy of such a model of delivering longitudinal care is demonstrated 
by the clear and dramatic impact on long-term survival revealed in this study. Collectively, 
these findings establish the importance and efficacy of community based rehabilitation 
programs as well as parental understanding and participation in ensuring the long-term 
survival of children living with myelomeningocele and hydrocephalus in Uganda.  
 A Shift  in Focus and New Initiatives at CCHU 
  
The findings of this study have catalyzed a shift in focus and changes in 
operational procedure at CCHU. The Hospital celebrated its ten-year anniversary 
recently, and while the first ten years of operation were characterized by an effort to 
perform a greater number of procedures each successive year, the findings of this study 
have shifted attention to ensuring long-term survival after surgery. 
Several new initiatives at CCHU aim to improve long-term survival in 
myelomeningocele patients. To address the lack of understanding among parents about 
their child’s disease and the need for long-term care, the author developed a brief 
illustrated lecture that is presented to parents of children admitted to the hospital for 
myelomeningocele closure with time following for discussion and questions. In addition 
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to explaining the basic pathophysiology of myelomeningocele, the lecture emphasizes the 
importance of repositioning children to avoid pressure sores, the necessity of follow-up to 
achieve social urine and bowel continence, and the fact that children with 
myelomeningocele are capable of growing up to become contributing members of their 
communities.   
With the help of illustrator Bryan Hong (Yale Medical School, Class of 2010), this 
author created a children’s book entitled “Everyone is Different” (Appendix A). This 
book, which is being reproduced in Uganda and is given to every child admitted for 
myelomeningocele closure at CCHU, covers the same topics as the parent lecture 
although from the perspective of a young child living in Uganda coping with the 
challenges of paraplegia and urinary incontinence. It is our hope that these resources will 
impress upon children, their caregivers, and their communities that these patients with 
myelomeningocele are worthwhile individuals capable of contributing to society and 
deserving of the care and resources to ensure their survival.  
As a direct result of the findings reported here, CCHU has begun funding and 
expanding community-based rehabilitation programs throughout southeastern Uganda 
in the hopes of replicating the survival benefit identified in this study in communities with 
community-based rehabilitation programs. In addition, the Hospital has devoted one 
social worker full time to the task of tracking patients who have missed follow-up 
appointments to ensure that patients do not fall out of contact with the hospital staff. 
Enrollment of myelomeningocele patients for a subsequent follow-up study has already 
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begun at CCHU, with data collection to begin in five years in order to assess the impact 
of these initiatives on long-term survival. 
 
Conclusions: Practical  Barriers to Neurosurgical  Care in the Developing 
World 
The finding that five-year mortality is similar between patients treated with ETV 
and VP shunt implantation fails to support the hypothesized survival benefit for 
hydrocephalic children in a developing country treated with ETV. However, it would be 
premature to conclude from this finding alone that there is no actual survival advantage to 
treatment with ETV in this setting. Taken collectively, the findings from this study 
demonstrate that long-term rehabilitative care is a far more powerful determinant of 
mortality than how hydrocephalus is treated or even whether a patient develops 
hydrocephalus at all. It is entirely possible that there exists a difference in long-term 
survival between patients treated with ETV and shunt implantation, but that this 
difference was obscured by the powerful effect of long-term rehabilitative care.  
 While this study focuses attention on long-term rehabilitative care as the critical 
determinant of long-term survival in this population, on a broader level it illustrates the 
profound difficulties of treating neurosurgical disease in a developing country. In 
Uganda, hydrocephalus is a unique pathophysiological entity accompanied by barriers to 
treatment which are inconceivable to citizens of developed nations. Understanding these 
barriers, and the resilient beliefs upon which these barriers are constructed, is critical to 
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formulating successful approaches to the treatment of disease. This study demonstrates 
that ignoring these beliefs and barriers comes at the cost of patients’ lives.  
While it is important to acknowledge and understand the profound differences 
between the developed and developing world, we should not forget the commonalities 
which transcend cultures and continents. The importance of patient education and 
participation in treatment plans as an essential component in producing positive 
outcomes has been demonstrated time and again in the developed world. This is no 
different in the case of Uganda, and it is perhaps even more important in a setting in 
which we seek to deliver care across linguistic and cultural barriers. For all of the many 
differences between Uganda and the United States, one should not forget that some 
aspects of delivering effective medical care are universal.  
 The delivery of neurosurgical care to the residents of the developing world is an 
imperative which cannot be ignored. Adapting a technically complex and technologically 
dependent field to a developing country is fraught with difficulties, however one must not 
forget the many practical barriers beyond the operating room which may stand in the way 
of providing effective treatment. While cultural beliefs and practical barriers to treatment 
may be considered outside of the purview of neurosurgery in the developed world, these 
issues must be taken into account if the field of neurosurgery is to provide effective cures 
in the developing world. Indeed, it is these practical issues of culture and communication 
which must be considered if we are to ensure that as we advance neurosurgical care in 
developed nations, that we do not leave the rest of the world behind.  
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Appendix A: Everyone is Different 
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